Report Content
Chapter 1 Methodology & Scope
1.1 Market scope & definitions
1.2 Research design
1.2.1 Research approach
1.2.2 Data collection methods
1.3 Base estimates & calculations
1.3.1 Base year calculation
1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
1.5.1 Primary sources
1.5.2 Data mining sources
Chapter 2 Executive Summary
2.1 Industry 360° synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Increasing prevalence of chronic diseases across the globe
3.2.1.2 Growing demand for outsourcing clinical trials to CROs
3.2.1.3 Rise in government and non-government funding for clinical trials
3.2.1.4 Growing opportunities for conducting clinical trials in countries of Asia Pacific
3.2.2 Industry pitfalls & challenges
3.2.2.1 Lack of skilled workforce in clinical research
3.2.2.2 Infrastructural barriers in developing countries
3.2.2.3 Challenges faced in North America & Europe for conducting clinical trials
3.3 Growth potential analysis
3.4 Clinical trials volume analysis
3.4.1 Clinical trials volume analysis, by region, 2021-2023
3.4.2 Clinical trials volume analysis, by phase of development, 2021-2023
3.4.3 Clinical trials volume analysis, by indication, 2021-2023
3.5 Regulatory landscape
3.5.1 U.S.
3.5.2 Europe
3.5.3 Asia Pacific
3.5.3.1 Singapore
3.5.3.2 Malaysia
3.5.3.3 Indonesia
3.5.3.4 Thailand
3.5.3.5 South Korea
3.5.3.6 Philippines
3.6 Clinical trails - Asia Pacific advantage
3.7 Porters anlaysis
3.8 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.2 Company matrix analysis
4.3 Merger & acquisition landscape
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Strategy dashboard
Chapter 5 Market Estimates and Forecast, By Phase, 2021 – 2032 ($ Mn)
5.1 Key trends
5.2 Phase I
5.3 Phase II
5.4 Phase III
5.5 Phase IV
Chapter 6 Market Estimates and Forecast, By Study Design, 2021 – 2032 ($ Mn)
6.1 Key trends
6.2 Interventional study
6.3 Observational study
6.4 Expanded access study
Chapter 7 Market Estimates and Forecast, By Service Type, 2021 – 2032 ($ Mn)
7.1 Key trends
7.2 Outsourcing service
7.3 In-house service
Chapter 8 Market Estimates and Forecast, By Therapeutic Area, 2021 – 2032 ($ Mn)
8.1 Key trends
8.2 Autoimmune disease
8.3 Oncology
8.4 Cardiology
8.5 Infectious disease
8.6 Dermatology
8.7 Ophthalmology
8.8 Neurology
8.9 Hematology
8.10 Other therapeutic areas
Chapter 9 Market Estimates and Forecast, By Region, 2021 – 2032 ($ Mn)
9.1 Key trends
9.2 North America
9.2.1 U.S.
9.2.2 Canada
9.3 Europe
9.3.1 Germany
9.3.2 UK
9.3.3 France
9.3.4 Spain
9.3.5 Italy
9.3.6 Poland
9.3.7 Netherlands
9.3.8 Switzerland
9.3.9 Rest of Europe
9.4 Asia Pacific
9.4.1 China
9.4.2 Japan
9.4.3 India
9.4.4 Australia
9.4.5 South Korea
9.4.6 Singapore
9.4.7 Malaysia
9.4.8 Indonesia
9.4.9 Thailand
9.4.10 Philippines
9.4.11 Rest of Asia Pacific
9.5 Latin America
9.5.1 Brazil
9.5.2 Mexico
9.5.3 Argentina
9.5.4 Rest of Latin America
9.6 Middle East and Africa
9.6.1 Saudi Arabia
9.6.2 South Africa
9.6.3 UAE
9.6.4 Rest of Middle East and Africa
Chapter 10 Company Profiles
10.1 Charles River Laboratories (MPI Research)
10.2 Clinipace Inc.
10.3 Eli Lilly and Company
10.4 ICON plc
10.5 IQVIA Inc
10.6 Laboratory Corporation of America Holdings (Covance Inc)
10.7 Medpace, Inc.
10.8 Merck & Co
10.9 Parexel International Corporation
10.10 Pfizer Inc.
10.11 SGS SA
10.12 Syneos Health
10.13 The Emmes Company, LLC
10.14 Thermo Fisher Scientific (PPD Inc)
10.15 Veeda Clinical Research
10.16 Worldwide Clinical Trials
10.17 WuXi AppTech
